The estimated Net Worth of Stephen B. Howell is at least $444 Thousand dollars as of 8 April 2019. Stephen Howell owns over 4,000 units of Abeona Therapeutics Inc stock worth over $444,371 and over the last 15 years Stephen sold ABEO stock worth over $0.
Stephen has made over 1 trades of the Abeona Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Stephen bought 4,000 units of ABEO stock worth $31,080 on 8 April 2019.
The largest trade Stephen's ever made was buying 4,000 units of Abeona Therapeutics Inc stock on 8 April 2019 worth over $31,080. On average, Stephen trades about 1,000 units every 0 days since 2009. As of 8 April 2019 Stephen still owns at least 79,494 units of Abeona Therapeutics Inc stock.
You can see the complete history of Stephen Howell stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, , NEW YORK, NY, 10019.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: